spacer
home > ict > winter 2018 > promoting patterns
PUBLICATIONS
International Clinical Trials

Promoting Patterns

The clinical trial industry is transforming, and the vision for this is simple: embrace quality and automation across the clinical trial spectrum and move closer to zero-delay trials. Why? It provides better, faster results, offers more information for sponsors, allows more innovation for CROs, and, most importantly, presents expedited outcomes for patients in need. This transformation is just beginning and requires that we challenge ourselves, our teams, partners, and clients – the entire clinical trial industry – to work smarter and eliminate preventable delays.

Data Dilemmas

Drug or device trials are fundamentally science experiments. Everyone has some familiarity with how that works from those exciting high school or college labs where one measured some Newtonian physics principle. However, unlike those, in clinical trials, the outcome is unknown, and the data are never as crisp and predictable. For the most part, the signalto- noise ratio is exceedingly small. If the data collection or the analysis processes adds more noise to the system, the signal may become undetectable. When that happens, therapies that might have helped patients in need may never be approved because the data was not handled appropriately.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Abraham Gutman founded AG Mednet in 2005 and leads the company’s mission to improve, automate, and expedite outcomes in clinical trials by ensuring quality and compliance within drug, biologic, and device trials. Abraham holds a BA in computer science from Cornell University and an MSc in computer science from Yale University, US.
spacer
Abraham Gutman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Tagrisso approved in the US for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer

AstraZeneca’s Tagrisso (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumour resection with curative intent. Tagrisso is indicated for EGFRm patients whose tumours have exon 19 deletions or exon 21 L858R mutations as detected by an approved test.
More info >>

White Papers

Inhaler Adherence: Exploring Key Factors

Aptar Pharma

Aptar Pharma recently hosted an expert panel roundtable on “Inhaler Adherence”. This international scientific forum was held in Paris, France on November 29th 2013. The roundtable was organized to explore and exchange views on the issues which may influence inhaler adherence/ compliance with a particular focus on asthma and C.O.P.D. therapies and their corresponding inhaler devices (MDIs, DPIs).
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement